Icatibant Peptide: Firazyr, HAE Attacks and Bradykinin Evidence
Icatibant peptide guide covering Firazyr, bradykinin B2 antagonism, hereditary angioedema attack evidence, self-administration and safety limits.
Icatibant is a peptide medicine with a very specific job: on-demand treatment of acute hereditary angioedema attacks in adults. It is sold as Firazyr in the United States and is described in the label as a synthetic decapeptide and bradykinin B2 receptor antagonist.
That specificity matters. Icatibant is not an allergy supplement, not a general anti-inflammatory peptide and not a casual swelling remedy. It targets a bradykinin-driven mechanism in hereditary angioedema, or HAE, where C1 inhibitor deficiency or dysfunction can lead to recurrent swelling of the skin, abdomen or airway.
For peptide background, read what peptides are, the peptide glossary, and the peptide half-life guide. For other approved injectable peptide medicines with product-specific labels, compare octreotide, leuprolide, and bremelanotide. For general injection principles, see how to inject peptides safely and the peptide storage guide, but those pages do not replace the Firazyr label or an HAE action plan.
This guide is educational and not medical advice. HAE attacks can become life-threatening, especially when the throat or voice box is involved. Diagnosis, rescue medication selection, training, repeat dosing and emergency care planning belong with a qualified clinician.
Icatibant At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic decapeptide with five non-proteinogenic amino acids. |
| US brand | Firazyr, a single-dose prefilled syringe product. |
| Main labeled use | Acute attacks of hereditary angioedema in adults 18 years and older. |
| Target | Bradykinin B2 receptor. |
| Route | Subcutaneous injection in the abdominal area under label instructions. |
| Main trial endpoint | Time to clinically meaningful symptom reduction during acute attacks. |
| Main safety frame | Injection-site reactions, laryngeal attack emergency care and cardiovascular theoretical risk in acute ischemia contexts. |
Why Bradykinin Matters In HAE
Hereditary angioedema is not the same as ordinary hives or histamine-driven allergy. In the classic C1 inhibitor-related forms, the contact system and kallikrein pathway can generate excess bradykinin. Bradykinin increases vascular permeability, which allows fluid to leak into tissues and produce swelling.
That explains why antihistamines or steroids are not the core evidence story for HAE attacks. The target is bradykinin biology. Icatibant blocks the bradykinin B2 receptor, competing with bradykinin at the receptor involved in swelling, pain and vascular permeability.
The Firazyr label describes icatibant as a competitive antagonist selective for the bradykinin B2 receptor. It also states that HAE is caused by absence or dysfunction of C1 esterase inhibitor, a key regulator of the cascade that leads to bradykinin production. That mechanistic match is why icatibant was studied as an acute-attack treatment.
What The FAST Trials Measured
The pivotal evidence for icatibant comes from the FAST program. These were not general swelling studies. They enrolled patients with hereditary angioedema attacks and measured symptom relief over time.
The New England Journal of Medicine report combined FAST-1 and FAST-2. FAST-1 compared icatibant with placebo. FAST-2 compared icatibant with oral tranexamic acid over two days. Icatibant was given as a single 30 mg subcutaneous dose. The primary endpoint was median time to clinically significant symptom relief.
FAST-3 was a later randomized placebo-controlled phase 3 trial. In cutaneous or abdominal attacks, PubMed's abstract reports that icatibant reduced the median time to at least 50% symptom-severity reduction compared with placebo. The DailyMed clinical-studies section gives the label-level figure for Trial 1: 2.0 hours with Firazyr versus 19.8 hours with placebo for a 50% reduction in a 3-item visual analog score.
| Evidence layer | What it adds | Practical reading |
|---|---|---|
| FAST-1 and FAST-2 | Randomized adult acute-attack evidence. | Supports an on-demand HAE attack role, not prevention. |
| FAST-3 | Placebo-controlled phase 3 evidence for acute attacks. | Confirms faster symptom reduction versus placebo in trial conditions. |
| Open-label extensions | Repeated treatment across many attacks. | Useful for recurrence and repeat-use context, but less controlled than blinded trials. |
| Icatibant Outcome Survey | Real-world registry experience over 10 years. | Supports routine-care context and self-administration patterns. |
| WAO/EAACI guideline | International HAE management framework. | Places icatibant among on-demand therapies, not as a standalone plan. |
Repeated Attacks And Self-Administration
HAE is recurrent, so a single-attack trial is only part of the story. Open-label extension studies examined repeat treatment across multiple attacks. The Firazyr label reports that in controlled-trial extensions, 225 patients were treated with 1,076 doses for 987 acute HAE attacks. In the first five icatibant-treated attacks, median times to a 50% reduction in the composite symptom score were similar across attacks, and most attacks were treated with a single dose.
Self-administration is also central to real-world use. The label says patients may self-administer after training under healthcare-professional guidance. That is not the same as unsupervised use. It means the medication can be part of a preplanned HAE action plan once diagnosis, supply, technique, repeat-dose rules and emergency instructions are established.
The Icatibant Outcome Survey adds routine-care context. Its 10-year review describes thousands of attacks in registry data and reports that earlier treatment facilitated by self-administration was associated with faster resolution and shorter attack duration in published IOS analyses. Registry data can complement trials, but it cannot remove the need for a clinician-led plan.
Laryngeal Attacks Are Different
The label is direct about throat involvement. For laryngeal attacks, patients should seek immediate medical attention in an appropriate healthcare facility after treatment with Firazyr. The reason is airway obstruction risk.
This point should not be softened. A medication that can be self-administered does not make airway attacks safe to manage at home. HAE action plans usually need to cover when to treat, when to repeat, when to call emergency services, which hospital knows the diagnosis, and what backup therapy is available.
Any source that discusses icatibant without this laryngeal warning is missing one of the most important safety boundaries.
Safety Limits
Icatibant's most common adverse reactions are local injection-site reactions. The Firazyr label says injection-site reactions occurred in almost all patients in controlled trials. These can include bruising, burning, erythema, numbness, pain, pressure, pruritus, swelling, warmth and similar local effects.
Other label-listed adverse reactions reported more often than placebo included pyrexia, increased transaminases, dizziness and rash. The patient section also lists nausea and headache. Drowsiness, tiredness and dizziness are reasons to avoid driving or machinery if they occur.
| Safety issue | Why it matters |
|---|---|
| Injection-site reactions | Very common in trials and usually central to tolerability discussions. |
| Laryngeal attacks | Airway swelling needs immediate medical attention even after treatment. |
| Repeat dosing limit | The label allows repeat injections at least 6 hours apart, with no more than 3 doses in 24 hours. |
| Pediatric status | US label says safety and effectiveness below 18 years have not been established. |
| Acute ischemia caution | Nonclinical data create a theoretical cardiovascular concern during acute coronary ischemia, unstable angina or recent stroke. |
| ACE inhibitor interaction theory | Label notes a potential pharmacodynamic interaction because ACE inhibitors affect bradykinin biology. |
The pediatric point deserves careful wording. A pediatric phase 3 study exists and has been published, but the current US Firazyr label remains adult-only. That means readers should not infer a US pediatric indication from the literature alone.
Icatibant Versus Other HAE Attack Treatments
HAE treatment is not one drug. The international WAO/EAACI guideline discusses on-demand therapy, prophylaxis, diagnosis and attack planning. Depending on the country and patient, acute-attack options can include C1 inhibitor products, kallikrein-targeting options and bradykinin receptor antagonism.
Icatibant's distinguishing feature is receptor blockade: it targets the bradykinin B2 receptor after bradykinin has been generated. C1 inhibitor replacement works earlier in the cascade. Kallikrein inhibitors target a different upstream step. Those mechanisms can all sit inside HAE care, but they are not interchangeable without medical context.
The label also keeps the indication narrow: acute attacks in adults. It is not a preventive medicine, not a daily immune support peptide and not a general angioedema product for every cause. Some swelling is histamine-driven. Some is ACE inhibitor-associated. Some has other causes. HAE diagnosis matters.
How To Evaluate Icatibant Claims
Start with the exact condition. Does the source say hereditary angioedema with C1 inhibitor deficiency or dysfunction, or does it use vague swelling language?
Next, check the endpoint. Trial evidence focuses on time to symptom relief in acute attacks. It does not establish broad anti-inflammatory benefits.
Then check the route and product. Firazyr is a sterile, single-dose prefilled syringe product for subcutaneous injection. That is different from a research-market vial, an oral supplement or a home-mixed product.
Also check whether the source mentions laryngeal attacks and emergency care. That is a core safety requirement.
Finally, check whether adult and pediatric evidence are being separated. The current US label is adult-only even though pediatric data exist in the literature.
For general calculator context, PeptideStat calculators and the peptide chemistry tool are educational. They are not substitutes for the Firazyr label, patient instructions, sharps disposal rules or an HAE action plan.
Bottom Line
Icatibant is a real peptide medicine with a focused evidence base. It is a synthetic decapeptide that blocks bradykinin B2 receptors and has randomized trial plus registry evidence for acute hereditary angioedema attacks in the right setting.
The narrowness is the point. Icatibant is not a general swelling peptide, not a preventive HAE plan by itself and not a replacement for emergency care when the airway is involved. The strongest reading is label-specific: adult acute HAE attacks, trained use, repeat-dose limits, injection-site reactions and urgent evaluation for laryngeal symptoms.
References
DailyMed. Firazyr (icatibant acetate) prescribing information.
Cicardi M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Lumry WR, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
Cicardi M, et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
Riedl MA, et al. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
Maurer M, et al. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
Maurer M, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.
Farkas H, et al. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
Bernstein JA, et al. Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus.